SUBSCRIBE
SUBSCRIBE
News   Business

Crucell N.V., DSM Biologics Sign PER.C6 License Agreement with Daiichi Sankyo, Inc.

November 16, 2007 | 
1 min read
AMSTERDAM, Nov. 16, 2007 (Thomson Financial delivered by Newstex) -- Crucell (NASDAQ:CRXL) NV and Royal DSM NV's (OOTC:RDSMY) DSM Biologics said they have signed a license agreement with Daiichi Sankyo Company Limited.
Alliances Europe
Daiichi Sankyo
MORE ON THIS TOPIC
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Feb 19, 2020 Foster City / CA / USA - Gilead corporate headquarters in Silicon Valley; Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs
Infectious disease
Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership
July 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Fund raising Capital Donation. Funds Support Concept. Fundraising. Collecting donations in jar.
Series B
Nuclidium Nets $99M Series B for Copper-Based Radiopharma Platform
July 10, 2025
 · 
2 min read
 · 
Tristan Manalac
A hand in a medical or laboratory glove holds a laboratory flask with coins with dollar sign. Investments in laboratory research and science. Concept of profit, making money, business. Modern design. Copy space.
Gene therapy
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M
July 9, 2025
 · 
1 min read
 · 
Dan Samorodnitsky